A Randomized Controlled Study of the Acute and Chronic Effects of Cooling Therapy for MS
Neurol 60:1955-1960, NASA/MS Cooling Study Group, 2003
Cognitive Presentation of Multiple Sclerosis: Evidence for a Cortical Variant
JNNP 74:872-877, Zarei,M.,et al, 2003
High- and Low-Risk Profiles for the Development of Multiple Sclerosis Within 10 Years After Optic Neuritis
Arch Ophthalmol 121:944-949, Optic Neuritis Study Group, 2003
Peripheral Third Cranial Nerve Enhancement in Multiple Sclerosis
AJNR 24:1390-1395, Bhatti,M.T.,et al, 2003
Concurrence of Multiple Sclerosis and Intracranial Glioma. Report of a Case and Review of the Literature.
Clin Neuropathol 22:304-308, Shuangshoti,S.,et al, 2003
Constipation in Neurological Diseases
JNNP 74:13-19, Winge,K.,et al, 2003
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 348:14-23, Miller,D.H.,et al, 2003
Mitoxantrone in Progressive Multiple Sclerosis: A Placebo-Controlled, Double-Blind, Randomised, Multicentre Trial
Lancet 360:2018-2025, Hartung,H.,et al, 2002
Copaxone's Effect on MRI-Monitored Disease in Relapsing MS is Reproducible and Sustained
Neurol 59:1284-1286, Wolinsky,J.S.,et al, 2002
Cause and Prognosis of Nontraumatic Sixth Nerve Palsies in Young Adults
Ophthalmology 109:1925-1928, Peters III,G.B.,et al, 2002
Randomized, Comparative Study of Interferon B-1a Treatment Regimens in MS
Neurol 59:1496-1506,1482, Panitch,H.,et al, 2002
Clinicopath Conf., Takayasu's Arteritis
NEJM 347:2057-2065, Case 39-2002, 2002
Prognosis for Gross Motor Function in Cerebral Palsy
JAMA 288:1357-1363,1399, Rosenbaum,P.L., et al, 2002
A Blinding Combination
Lancet 360:1220, Matthews,B.N.,et al, 2002
Therapy-Related Acute Myeloblastic Leukemia After Mitoxantrone Treatment in a Patient with MS
Neurol 59:954-955, Brassat,D.,et al, 2002
Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002
Tourette's Syndrome
Lancet 360:1577-1586, Leckman,J.F., 2002
A Randomized, Double-Blind, Dose-Comparison Study of Weekly Interferon B-1a in Relapsing MS
Neurol 59:1507-1517,1482, Clanet,M.,et al, 2002
Diagnostic Criteria for Idiopathic Intracranial Hypertension
Neurol 59:1492-1495, Friedman,D.I. &Jacobson,D.M., 2002
Nonmotor Fluctuations in Parkinson's Disease
Neurol 59:408-413, Witjas,T.,et al, 2002
Progressive Ventricular Enlargement in Patients with Clinically Isolated Syndromes is Associated with the Early Development of Multiple Sclerosis
JNNP 73:141-147, Dalton,C.M.,et al, 2002
Predictors of Hemorrhagic Transformation After Intravenous Recombinant Tissue Plasminogen Activator
Stroke 33:2047-2052, Selim,M.,et al, 2002
Lesions of the Corpus Callosum: MR Imaging and Differential Considerations in Adults and Children
AJR 179:251-257, Bourekas,E.C.,et al, 2002
Interferon Beta but not Glatiramer Acetate Therapy Aggravates Headaches in MS
Neurol 59:636-639, Pollmann,W.,et al, 2002
Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002
Is a "Vanishing Tumor" Always a Lymphoma?
Neurol 59:762-764, Bromberg,J.E.C.,et al, 2002
Assessment of Normal-Appearing White and Gray Matter in Patients with Primary Progressive Multiple Sclerosis
Arch Neurol 59:1406-1412, Rovaris,M.,et al, 2002
CADASIL Mimicking Primary Angiitis of the Central Nervous System
Arch Neurol 59:1480-1483, Engelter,S.T.,et al, 2002
Proton MR Spectroscopy of Tumefactive Demyelinating Lesions
AJNR 23:1378-1386, Saindane,A.M.,et al, 2002
Acute Disseminated Encephalomyelitis
Neurol 59:1224-1231, Tenembaum,S.,et al, 2002
T2-weighted MRI Differentiates Multiple System Atrophy from Parkinson's Disease
Neurol 59;1265-1267, Kraft,E.,et al, 2002
Early Onset Multiple Sclerosis
Neurol 59:1006-1010, Boiko,A.,et al, 2002
MRI Predictors of Early Conversion to Clinically Definite MS in the CHAMPS Placebo Group
Neurol 59:998-1005, CHAMPS Study Group, 2002
Potentially Reversible Conditions in 1000 Consecutive Memory Clinic Patients
JNNP 73:390-394, Hejl,A.,et al, 2002
Bacterial Infection as a Cause of Multiple Sclerosis
Lancet 360:352-353, Wolfson,C. &Talbot,P., 2002
Acquired Sexual Parphilia in Patients with Multiple Sclerosis
Arch Neurol 59:1006-1010, Frohman,E.M.,et al, 2002
Mimic Syndromes in Sporadic Cases of Progressive Spinal Muscular Atrophy
Neurol 58:1593-1596, Visser,J.,et al, 2002
Efficacy and Safety of Modafinil (Provigil) for the Treatment of Fatigue in Multiple Sclerosis: A Two Centre Phase 2 Study
JNNP 72:179-183,150, Rammohan,K.W.,et al, 2002
Differentiation of Multiple Sclerosis from Other Inflammatory Disorders and Cerebrovascular Disease: Value of Spinal MR Imaging
Radiology 223:46-56, Bot,J.C.J.,et al, 2002
Interferon Beta-1a for Early Multiple Sclerosis: CHAMPS Trial Subgroup Analyses
Ann Neurol 51:481-490, Beck,R.W.,et al, 2002
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Euthanasia and Physician-Assisted Suicide Among Patients with Amyotrophic Lateral Sclerosis in the Netherlands
NEJM 346:1638-1644, Veldink,J.H.,et al, 2002
Multiple Sclerosis
Lancet 359:1221-1231, Compston,A. &Coles,A., 2002
Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS
Neurol 58:1404-1407,1323, Killestein,J.,et al, 2002
Patients with Multiple Sclerosis and Risk of Type 1 Diabetes Mellitus in Sardinia,Italy: A Cohort Study
Lancet 359:1461-1465,1450, Marrosu,M.G.,et al, 2002
Refractory Status Epilepticus
Arch Neurol 59:205-210,188, Mayer,S.A.,et al, 2002
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Plasma Exchange for Severe Attacks of CNS: Demyelination: Predictors of Response
Neurol 58:143-146, Keegan,M.,et al, 2002